gov ID: NCT00551031). The four study arms in older adult subjects

were double-blinded for dose but open-label for vaccination route, whereas the fifth arm in younger adults was open-label. The primary objectives of the study were to demonstrate that the GMTs and seroconversion rates of each ID vaccine in older adults were: (i) non-inferior to those of the SD vaccine in older adults for each immunizing strain and (ii) superior to those of the SD vaccine for at least two of the three strains once non-inferiority was demonstrated. The secondary objectives of the study were to describe: (i) the post-vaccination seroconversion rates and GMTs of older adult HD vaccine recipients compared to those of younger adult SD vaccine recipients; (ii) the

seroprotection rates of all groups; GW3965 chemical structure and (iii) the safety profiles of the vaccines in all groups. The study was performed at 31 centers in the US between October 24, 2007 and June 2, 2008. The study was approved by a central institutional review board and five local institutional review boards and was conducted in accordance with the Edinburgh revision of the Declaration of Helsinki and International Conference on Harmonization Good Clinical Practice and Good Laboratory Practice guidelines. All subjects provided written informed consent before being enrolled in the trial. Subjects were medically stable, ambulatory, older adults (≥65 years of age) or younger adults (18–49 years of age). Women could not be pregnant or breastfeeding and if of child-bearing potential had SB203580 ic50 to be using an effective method of contraception within 4 weeks before and after vaccination. Subjects were excluded if they

had any of the following: known sensitivity to any of the vaccine components or to influenza vaccine; vaccinated against influenza within 6 months or any other vaccination within 4 weeks; history of Guillain-Barré syndrome; known or suspected immunodeficiency; immunosuppressive therapy within 6 months or long-term systemic corticosteroid MTMR9 therapy for more than 2 consecutive weeks within 3 months; bleeding disorder or received anticoagulants within 3 weeks; seropositive for human immunodeficiency virus, hepatitis B, or hepatitis C; received blood or blood-derived products within 3 months; or any other disease, condition, or treatment that might, in the opinion of the investigator, interfere with the assessment of immune responses or blood sample collection. Target enrollment in older adult subjects was 600 for each of the ID vaccine groups, 300 for the SD vaccine group, and 300 for the HD vaccine group. Target enrollment for the younger adult SD group was 150. Assuming a drop-out rate of 5% and based on data from similar studies comparing ID and IM TIVs [14] and [15], at α = 0.05, the power to meet the primary objectives for the 15 μg ID vaccine was 95.2% for the H1N1 strain, 98.6% for the H3N2 strain, and 71.